Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Methods for evaluating biological response modifiers]

J L Harousseau1

  • 1Service d'hématologie clinique, Hôtel-Dieu, CHU de Nantes, 1, place Alexis-Ricordeau, 44035 Nantes.

Bulletin Du Cancer
|January 26, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis.

Cancer treatment reviews·2016
Same author

Integration of Cost-Effectiveness Assessment in the Market Access Scheme of Drugs and Medical Devices In France.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

Analysis of Cost-Effectiveness Assessments In France By The French National Authority For Health (Has).

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

Exploring Uncertainty in Economic Evaluation Of Medicines: A Review of The First Manufacturers' Submissions To the French National Authority For Health (Has).

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

A Cost-Effectiveness Analysis of Treatment for Mild to Moderate Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS) in France.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

Improvement of overall survival after allogeneic hematopoietic stem cell transplantation for children and adolescents: a three-decade experience of a single institution.

Bone marrow transplantation·2015
Same journal

[ONCONNECTE À L'EMPLOI, feedback after three years of a program to prepare for returning to work after cancer in Franche-Comté].

Bulletin du cancer·2026
Same journal

[Off-label use of venetoclax in myeloma].

Bulletin du cancer·2026
Same journal

[Cemiplimab - Adjuvant treatment for the cutaneous squamous cell carcinomas with high risk of relapse, operated and treated by radiotherapy].

Bulletin du cancer·2026
Same journal

Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study).

Bulletin du cancer·2026
Same journal

[Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)].

Bulletin du cancer·2026
Same journal

[Reirradiation: A new therapeutic paradigm in oncology].

Bulletin du cancer·2026
See all related articles

Biological response modifiers (BRMs) offer a novel cancer treatment approach. Evaluating BRM efficacy and toxicity presents unique challenges due to their properties and disease complexities.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Context:

  • Biological response modifiers (BRMs) represent a novel therapeutic strategy in cancer treatment.
  • Evaluating BRMs requires adapting methodologies used for conventional anticancer agents.
  • BRM assessment is complicated by their unique properties and the nature of the diseases they target.

Purpose:

  • To validate pharmacodynamic effects observed in preclinical models.
  • To determine the clinical benefit of BRMs for cancer patients.
  • To establish efficacy criteria including objective response rate, progression-free survival, and overall survival.

Summary:

  • Phase II studies may involve healthy volunteers to assess BRM effects.
  • Phase III trials compare BRMs against observation, placebo, or standard treatments.

Related Experiment Videos

  • Toxicity evaluation includes BRM-specific side effects like cytokine synthesis and immune stimulation.

    • Impact:

    • Provides a framework for evaluating novel cancer therapeutics.
    • Highlights the complexities in assessing biological response modifiers.
    • Informs clinical trial design and patient management strategies for BRM therapies.